ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company reported negative financial results after a series of positive quarters, with troubling metrics such as a return on equity of -24.97% and substantial operating losses.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a negative return on equity and rising raw material costs, while its recent operating profit has also decreased substantially.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a challenging financial landscape marked by a significant operating loss and rising raw material costs. The company faces negative return on equity and a high price-to-book ratio, indicating struggles in maintaining profitability compared to broader market performance.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a negative return on equity and substantial operating losses, amid rising raw material costs and a high price-to-book ratio.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company reported negative financial results after a series of positive quarters, with key metrics indicating ongoing challenges, including a negative return on equity and substantial operating losses.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,057 million, is currently operating at a loss, facing rising raw material costs and negative financial metrics amid a challenging market environment.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, trading at USD 9.08 on October 24, 2025. The company has faced financial challenges, including a negative return on equity and significant operating losses. Its stock has underperformed compared to broader market indices, raising concerns among stakeholders.

ARS Pharmaceuticals, Inc. has seen a significant intraday stock increase, contrasting with a slight decline in the S&P 500. While the company has shown short-term gains, it faces long-term challenges, including a notable decline over the past year and rising raw material costs, impacting its financial health.

ARS Pharmaceuticals, Inc. has recently revised its evaluation amid market challenges, with its stock price at $10.27. The company has experienced a significant decline over the past year, while showing resilience in shorter time frames. The evaluation reflects ongoing volatility in the pharmaceutical sector.

ARS Pharmaceuticals, Inc. has recently encountered a technical event known as a Death Cross, indicating potential shifts in market sentiment. The stock shows bearish trends across various indicators, including MACD and moving averages, while experiencing increased volatility. Despite a slight daily uptick, it has underperformed over the past year.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting significant volatility in its stock performance over the past year. The company reported a return of -29.61%, underperforming the S&P 500, and faced rising raw material costs, contributing to an operating loss of USD 47.33 million.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline from its previous high. The company has struggled with a negative operating profit and rising raw material costs, contributing to its challenging financial position amid a broader market recovery. Its market capitalization stands at USD 1,057 million.

ARS Pharmaceuticals, Inc. has faced significant challenges over the past year, with a notable decline in stock performance compared to the S&P 500. Recent evaluations indicate mixed technical indicators, reflecting a cautious outlook as the company navigates a volatile market environment and seeks strategic adjustments.

ARS Pharmaceuticals, Inc. has faced significant challenges over the past year, with a notable decline in stock performance compared to the S&P 500. Recent evaluations indicate mixed technical indicators, reflecting a cautious outlook as the company navigates a volatile market environment and seeks strategic adjustments.

ARS Pharmaceuticals, Inc. has reached a new 52-week low, reflecting a significant decline from its previous high. The company has faced a challenging year, with a notable drop in stock performance and disappointing financial results, including a substantial operating loss and rising raw material costs.